ClinicalTrials.gg
Active, not recruitingNCT04493853CAPItello-281Updated Sep 10, 2026Results posted

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

A Phase 3 interventional study of Capivasertib and Placebo in Hormone-Sensitive Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 323 sites in 32 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,012
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing capivasertib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 3 of them phase 3. capivasertib · Prostatic Neoplasms.

Enrollment
3rd of 10
1,012 · median 238
Started
2020
the only one that year
Phase 3
3 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
4 of 10
AstraZeneca

Among the 10 studies testing capivasertib in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 3 in phase 3, and was the 6th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 10 studies testing capivasertib in Prostatic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About capivasertib

capivasertib: first FDA approval 2023 (TRUQAP), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 130 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing capivasertib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.

03

Conditions studied

  • Hormone-Sensitive Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • De Novo Metastatic Prostate cancer
  • PTEN
  • PTEN deficiency
  • Hormones
  • Hormone-Sensitive
  • Androgen Deprivation Therapy
  • Capivasertib
  • Abiraterone
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asymptomatic or mildly symptomatic, -confirmed de novo hormone-sensitive prostate adenocarcinoma without small-cell tumours diagnosed within 180 days of randomisation
  • Consent to provide a FFPE tissue block (preferred) or slides. Tissue from bone is not acceptable
  • A valid PTEN IHC result indicating PTEN deficiency (centralized testing)
  • Metastatic disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion accurately assessed at baseline and suitable for repeated assessment with CT and/or MRI. PSMA PET identification only will not be eligible
  • Candidate for abiraterone and therapy
  • Ongoing ADT with GnRH analogue, or LHRH agonists or antagonist, or bilateral orchiectomy (regardless of method) is from 0 days to a max. of 93 days prior to randomisation
  • (ECOG)/WHO performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum of 12 weeks
  • Able and willing to swallow and retain oral medication
  • 7-day Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory(BFI) questionnaires and the analgesic diary during screening completed. Participants must complete a minimum of 4 successful assessments within a 7-day period prior to randomisation.
  • Agreement to remain abstinent (refrain from heterosexual intercourse) or use measures, and agreement to refrain from donating sperm
  • Capable of giving signed
  • Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples

Exclusion criteria

Exclusion Criteria:

  • Prior radical prostatectomy or definitive radiotherapy with therapeutic intent for prostate cancer. Palliative radiotherapy is allowed providing any wide field radiation therapy is completed more than 4 weeks before the start of study treatment
  • Major surgery (excluding placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, or internal stents) within 4 weeks of the start of study treatment
  • , or spinal cord compression (unless spinal cord compression is asymptomatic, treated and stable and not requiring for at least 4 weeks prior to start of study treatment)
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
  • Any of the following cardiac criteria:

    i. Mean resting interval (QTc) > 470 msec obtained from triplicate ECGs ii. History of QT prolongation associated with other medications that required discontinuation of that medication.

iii. Family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.

iv. Medical history significant for arrhythmia which is symptomatic or requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.

v. Any abnormalities in conduction or morphology of resting (eg, complete left bundle branch block, third-degree heart block) vi. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, or any concomitant medication known to significantly prolong the QT interval vii. Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft, angioplasty, myocardial infarction, angina pectoris.

viii. Congestive heart failure Grade ≥ 2 ix. Symptomatic hypotension - systolic blood pressure (SBP) \<90 mmHg and/or diastolic blood pressure (DBP) \<50 mmHg x. Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 95 mmHg).

  • Clinically significant abnormalities of glucose metabolism as defined by any of the following:

    i. Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment ii. ≥8.0% (63.9 mmol/mol)

  • Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    i. \< 1.5x 10\^9/L ii. count \< 100x 10\^9/L iii. \< 9 g/dL (\< 5.59 mmol/L) iv. (ALT) and aspartate aminotransferase (AST) > 2.5x (ULN) if no demonstrable liver or > 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total > 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. \< 50 mL/min (measured or calculated by Cockcroft and Gault equation)

  • As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or known active infection including , , and
  • unevaluable for both bone and soft tissue progression as defined by meeting both of the following criteria: i. a "superscan" of bone scan, and ii. no soft tissue lesion that can be assessed by criteria
  • nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining
  • Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent
  • Previous bone marrow transplant or solid organ transplant
  • History of another primary except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.
  • Treatment with any of the following:

    i. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment ii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iii. Any other chemotherapy, immunotherapy, medication (other than corticosteroids) or anticancer agents within 3 weeks of the first dose of study treatment. A longer washout may be required for drugs with a long half-life (eg, biologics) iv. Strong inhibitors or strong inducers of within 2 weeks before the start of study treatment (3 weeks for St John's wort). Note that adequate or dose reduction may be required for some CYP3A substrates prior to initiating Capivasertib dosing.

  • Drugs known to significantly prolong the QT interval and associated with Torsades de Pointes within 5 half-lives of the first dose of study treatment
  • Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives, whichever is longer.
  • History of to active or inactive of capivasertib, abiraterone, or drugs with a similar chemical structure or class.
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  • Any restriction or based on the local prescribing information that would prohibit the use of abiraterone.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,012 participants (actual)

Study arms

  • Experimental
    Capivasertib + Abiraterone

    Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.

    Drug: Capivasertib · Drug: Abiraterone Acetate

  • Placebo comparator
    Placebo + Abiraterone

    Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.

    Other: Placebo · Drug: Abiraterone Acetate

Interventions

  • 400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • OtherPlacebo

    matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.

    Also known as: ZYTIGA, Novadoz

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-free Survival (rPFS)

    rPFS is defined as the time from randomisation to radiographic progression, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST) for soft tissue and/or Prostate Cancer Working Group 3 (PCWG3) for bone, or death due to any cause for each study arm.

    Time frame: Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized

07

Results

Posted Sep 10, 2026

Participant flow

The study is active, not recruiting and conducted in 32 countries worldwide across 259 centres, with 1012 patients who were randomized up until 22nd February 2024.

Participant flow — Overall Study
MilestoneCapivasertib + AbirateronePlacebo + Abiraterone
Started507505
Completed00
Not completed507505
Withdrew: Death125134
Withdrew: Withdrawal by subject2723
Withdrew: As recorded on the case report form (crf).32
Withdrew: Patients ongoing study352346

Outcome measures

PrimaryRadiographic Progression-free Survival (rPFS)

rPFS is defined as the time from randomisation to radiographic progression, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST) for soft tissue and/or Prostate Cancer Working Group 3 (PCWG3) for bone, or death due to any cause for each study arm.

Time frame:
Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized
Reported as:
Median · Months
Radiographic Progression-free Survival (rPFS)
MonthsCapivasertib + AbirateronePlacebo + Abiraterone
Radiographic Progression-free Survival (rPFS)33.2 (25.8 to 44.2)25.7 (22.0 to 29.9)
Statistical analysis
  • Capivasertib + Abiraterone vs Placebo + Abiraterone · Log Rank · p = 0.034 · Hazard ratio (hr): 0.81 · 95% CI 0.66 to 0.98Analysed using a stratified Cox proportional hazards model adjusting for volume of disease/visceral metastases and geographic location. The CI was calculated using the profile likelihood approach. A hazard ratio \<1 favours Capivasertib + Abiraterone.

Adverse events

Collected over Adverse events, including SAEs, will be collected from time of signature of the informed consent form, throughout the treatment period and including the 30-day follow-up period after discontinuation of study drug, up to data cut-off for the Primary analysis (approximately 49 months). In Screening Part 1, only SAEs related to study procedures must be reported; AEs occurring during this period do not require reporting.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capivasertib + Abiraterone129/507 (25.4%)214/503 (42.5%)466/503 (92.6%)
Placebo + Abiraterone138/505 (27.3%)131/503 (26%)394/503 (78.3%)
Most frequent serious events
Showing 10 of 274
Most frequent serious events
EventCapivasertib + AbirateronePlacebo + Abiraterone
PneumoniaInfections and infestations19/50312/503
HyperglycaemiaMetabolism and nutrition disorders18/5030/503
Urinary tract infectionInfections and infestations15/5034/503
Rash maculo-papularSkin and subcutaneous tissue disorders12/5030/503
UrosepsisInfections and infestations9/5032/503
HypokalaemiaMetabolism and nutrition disorders9/5032/503
Acute kidney injuryRenal and urinary disorders9/5035/503
Diabetic ketoacidosisMetabolism and nutrition disorders6/5030/503
DiarrhoeaGastrointestinal disorders6/5031/503
PyrexiaGeneral disorders6/5030/503
Most frequent other events
Showing 10 of 35
Most frequent other events
EventCapivasertib + AbirateronePlacebo + Abiraterone
DiarrhoeaGastrointestinal disorders259/50339/503
HyperglycaemiaMetabolism and nutrition disorders173/50362/503
HypertensionVascular disorders100/503119/503
AnaemiaBlood and lymphatic system disorders116/50363/503
HypokalaemiaMetabolism and nutrition disorders109/50364/503
Rash maculo-papularSkin and subcutaneous tissue disorders105/50322/503
FatigueGeneral disorders80/50362/503
Alanine aminotransferase increasedInvestigations70/50367/503
Hot flushVascular disorders53/50368/503
Aspartate aminotransferase increasedInvestigations64/50359/503

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Capivasertib + AbirateronePlacebo + AbirateroneTotal
Mean67.4 ± 7.8267.1 ± 8.0367.2 ± 7.92
Age, Customized
Age, Customized(Participants)Capivasertib + AbirateronePlacebo + AbirateroneTotal
<509918
>=50 - <65165181346
>=65 - <75249220469
>=758495179
Sex: Female, Male
Sex: Female, Male(Participants)Capivasertib + AbirateronePlacebo + AbirateroneTotal
Female000
Male5075051012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Capivasertib + AbirateronePlacebo + AbirateroneTotal
Hispanic or Latino6166127
Not Hispanic or Latino438432870
Unknown or Not Reported8715
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Capivasertib + AbirateronePlacebo + AbirateroneTotal
Black or African American6612
American Indian or Alaska Native222244
Asian186189375
White266259525
Other134
Not Reported212041
Missing5611
Height
Height(cm)Capivasertib + AbirateronePlacebo + AbirateroneTotal
Mean170.55 ± 8.266170.45 ± 8.206170.50 ± 8.232
Weight
Weight(kg)Capivasertib + AbirateronePlacebo + AbirateroneTotal
Mean74.95 ± 15.62474.48 ± 15.33074.71 ± 15.472
Weight group (kg)
Weight group (kg)(Participants)Capivasertib + AbirateronePlacebo + AbirateroneTotal
<50121931
>=50 - <70194185379
>=70 - <90221228449
>=908073153

2 further baseline measures are reported on the registry.

08

Study locations

323 sites
  • Research Site
    Tucson, Arizona 85723, United States
  • Research Site
    Tucson, Arizona 85741, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Denver, Colorado 80211, United States
  • Research Site
    Lakewood, Colorado 80215, United States
  • Research Site
    Norwich, Connecticut 06360, United States
  • Research Site
    Fort Myers, Florida 33901-8101, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Geneva, Illinois 60134, United States
  • Research Site
    Lisle, Illinois 60532, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Troy, Michigan 48084, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    Asheville, North Carolina 28805, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Lancaster, Pennsylvania 17601, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Charleston, South Carolina 29401, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Roanoke, Virginia 24014, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Berazategui, B1884BBF, Argentina
  • Research Site
    Buenos Aires, 1426, Argentina
  • Research Site
    CABA, 1425, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1120AAT, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1280AEB, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    San Salvador de Jujuy, 4600, Argentina
  • Research Site
    Birtinya, 4575, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Kingswood, 2747, Australia
  • Research Site
    Orange, 2800, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Belém, 66073-005, Brazil
  • Research Site
    Belo Horizonte, 30110-022, Brazil
  • Research Site
    Florianópolis, 88020-210, Brazil
  • Research Site
    Fortaleza, 60135-237, Brazil
  • Research Site
    Jaú, 17210-120, Brazil
  • Research Site
    Joinville, 89201-260, Brazil
  • Research Site
    Porto Alegre, 90035-000, Brazil
  • Research Site
    Porto Alegre, 90050-170, Brazil
  • Research Site
    Porto Alegre, 90160-093, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Rio de Janeiro, 20230-130, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    Três Lagoas, 79601-001, Brazil
  • Research Site
    Pleven, 5804, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Plovdiv, 4109, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Sofia, 1756, Bulgaria
  • Research Site
    Sofia, 1797, Bulgaria
  • Research Site
    Varna, 9000, Bulgaria
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1H7, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    Santiago, 7500653, Chile
  • Research Site
    Santiago, 7500787, Chile
  • Research Site
    Santiago, 8420383, Chile
  • Research Site
    Temuco, 4781156, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100036, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410003, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Chengdu, 610000, China

Showing the first 100 of 323 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ; CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan;37(1):53-68. doi: 10.1016/j.annonc.2025.10.004. Epub 2025 Oct 19. PubMed 41120017 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data via secure research environment Vivli.org. A Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Oct 2024, 50 months.

Results were first posted in Sep 2026, 1 year 11 months after primary completion. A results delay was requested in Oct 2025.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 50 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2020
First posted
Jul 30, 2020
StartActual
Jul 13, 2020
Primary completionActual
Oct 7, 2024
CompletionEst.
Mar 31, 2027
Results delay requested
Oct 2, 2025
Results first posted
Sep 10, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04493853
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 30, 2020
Start date
Jul 13, 2020
Primary completion
Oct 7, 2024
Completion
Mar 31, 2027 (estimated)
Results posted
Sep 10, 2026
Last update
Sep 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion